We are live on ! Find out more
NEXI

NexImmune, Inc. Common Stock
NEXI

Delisted

NEXI was delisted on the 11th of July, 2024.

Back to rankings

29 hedge funds and large institutions have $1.45M invested in NexImmune, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

24% less funds holding

Funds holding: 38 → 29 (-9)

67% less capital invested

Capital invested by funds: $4.34M → $1.45M (-$2.89M)

69% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 13

Holders
29
Holders Change
-9
Holders Change %
-23.68%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
4
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$462K
2
Millennium Management
Millennium Management
New York
+$172K
3
Renaissance Technologies
Renaissance Technologies
New York
+$138K
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$27.7K
5
VF
Virtu Financial
New York
+$21.3K

Top Sellers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
-$513K
2
ACH
ArrowMark Colorado Holdings
Colorado
-$478K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$291K
4
BM
Bridger Management
New York
-$222K
5
KHCM
Kettle Hill Capital Management
New York
-$206K
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
1
Artal Group
Luxembourg
$292K – – –
Goldman Sachs
2
Goldman Sachs
New York
$225K +$462K +37,038 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$195K – – –
AO
4
Allen Operations
New York
$155K – – –
Millennium Management
5
Millennium Management
New York
$123K +$172K +13,769 +213%
Vanguard Group
6
Vanguard Group
Pennsylvania
$115K – – –
ECG
7
EPIQ Capital Group
California
$95K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$70K +$138K +11,080 +2,181%
PNC Financial Services Group
9
PNC Financial Services Group
Pennsylvania
$40.7K +$27.7K +2,222 +50%
MCM
10
M28 Capital Management
Connecticut
$32.4K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$15K – – –
CG
12
Caprock Group
Idaho
$13.8K – – –
BCM
13
Bridgeway Capital Management
Texas
$12.2K – – –
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$10.9K +$16K +1,280 New
BlackRock
15
BlackRock
New York
$10.3K +$6.55K +525 +45%
VF
16
Virtu Financial
New York
$10K +$21.3K +1,710 New
RJA
17
Raymond James & Associates
Florida
$7.44K – – –
First Manhattan
18
First Manhattan
New York
$6.08K -$20.6K -1,649 -62%
State Street
19
State Street
Massachusetts
$5.57K – – –
UBS Group
20
UBS Group
Switzerland
$3.99K +$998 +80 +14%
Northern Trust
21
Northern Trust
Illinois
$3.08K – – –
SSWM
22
Smith Salley Wealth Management
North Carolina
$2.67K – – –
ACH
23
ArrowMark Colorado Holdings
Colorado
$2.66K -$478K -38,324 -99%
DC
24
Davenport & Co
Virginia
$2.55K – – –
TRCT
25
Tower Research Capital (TRC)
New York
$2K -$3.69K -296 -53%
1
2

NEXI Hedge Fund Activity: Q4 2022 in Review

29 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in NexImmune, Inc. Common Stock (NEXI) for Q4 2022, worth a combined $1.45M — down 67% from $4.34M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NEXI and 4 opened new positions — a net loss of 9 holders — while 4 trimmed existing stakes and 7 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $462K. The largest seller was Slate Path Capital, exiting entirely with an estimated $513K sold.

  • 29 institutional investors held NexImmune, Inc. Common Stock (NEXI) as of Q4 2022, down from 38 in Q3 2022.
  • Funds reported $1.45M of NexImmune, Inc. Common Stock stock for Q4 2022, down 67% quarter-over-quarter.
  • 4 funds opened new NexImmune, Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -9 holders.
  • The largest NexImmune, Inc. Common Stock buyer in Q4 2022 was Goldman Sachs, an estimated $462K added.
  • The largest NexImmune, Inc. Common Stock seller in Q4 2022 was Slate Path Capital, an estimated $513K sold.

Based on aggregated 13F filings for Q4 2022.